Concin Nicole, Matias-Guiu Xavier, Cibula David, Colombo Nicoletta, Creutzberg Carien L, Ledermann Jonathan, Mirza Mansoor Raza, Vergote Ignace, Abu-Rustum Nadeem R, Bosse Tjalling, Chargari Cyrus, Espenel Sophie, Fagotti Anna, Fotopoulou Christina, Gatius Sonia, González-Martin Antonio, Lax Sigurd, Levy Bar, Lorusso Domenica, Macchia Gabriella, Marth Christian, Morice Philippe, Oaknin Ana, Raspollini Maria Rosaria, Schwameis Richard, Sehouli Jalid, Sturdza Alina, Taylor Alexandra, Westermann Anneke, Wimberger Pauline, Planchamp François, Nout Remi A
Department of Gynecology and Gynecological Oncology, Medical University of Vienna, Vienna, Austria.
Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain; Department of Pathology, Hospital Universitari de Bellvitge, Barcelona, Spain.
Lancet Oncol. 2025 Aug;26(8):e423-e435. doi: 10.1016/S1470-2045(25)00167-6.
In 2023, based on advances in the understanding of the pathological and molecular features of endometrial carcinoma, an updated International Federation of Gynaecology and Obstetrics (FIGO) staging system was published, aiming to better define prognostic groups and identify relevant treatment subgroups by including factors reflecting tumour biology (histological subtypes, lymphovascular space invasion, and molecular classification) alongside refinements of anatomical factors (peritoneal carcinomatosis and lymph node metastasis). As part of its mission to improve the quality of care for people with gynaecological cancers, the European Society of Gynaecological Oncology (ESGO), European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) updated the ESGO-ESTRO-ESP evidence-based guidelines published in 2021 by incorporating this revised FIGO staging and the large body of new evidence addressing the management of endometrial carcinoma. The development process of these guidelines was based on a systematic literature review and critical appraisal process involving an international multidisciplinary development group consisting of 30 experts from relevant disciplines (gynaecological oncology, radiation oncology, medical oncology, and pathology). A patient representative was also included. Before publication, the guidelines were reviewed by 225 independent international practitioners in cancer care delivery and three patient representatives from Asia, Europe, North Africa, North America, the Middle East, and South America to ensure a global perspective. These guidelines comprehensively cover diagnosis, management, follow-up, and patient education. Management includes surgical and adjuvant therapy according to the stage of the disease, and metastatic and recurrent disease. The management algorithms and the principles of radiotherapy and pathological evaluation are also defined.
2023年，基于对子宫内膜癌病理和分子特征认识的进展，国际妇产科联盟（FIGO）发布了更新的分期系统，旨在通过纳入反映肿瘤生物学的因素（组织学亚型、淋巴血管间隙浸润和分子分类）以及完善解剖学因素（腹膜癌转移和淋巴结转移），更好地界定预后分组并识别相关治疗亚组。作为其提高妇科癌症患者护理质量使命的一部分，欧洲妇科肿瘤学会（ESGO）、欧洲放射肿瘤学会（ESTRO）和欧洲病理学会（ESP）通过纳入修订后的FIGO分期以及大量关于子宫内膜癌管理的新证据，对2021年发布的ESGO-ESTRO-ESP循证指南进行了更新。这些指南的制定过程基于系统的文献综述和批判性评估过程，该过程涉及一个由来自相关学科（妇科肿瘤学、放射肿瘤学、医学肿瘤学和病理学）的30名专家组成的国际多学科制定小组。还纳入了一名患者代表。在发布之前，指南由225名独立的国际癌症护理从业者以及来自亚洲、欧洲、北非、北美、中东和南美的三名患者代表进行了审查，以确保具有全球视野。这些指南全面涵盖了诊断、管理、随访和患者教育。管理包括根据疾病分期进行手术和辅助治疗，以及转移性和复发性疾病的治疗。还定义了治疗算法以及放疗和病理评估的原则。
